Jayaraman Pushkala, Rajagopal Madhumitha, Paranjpe Ishan, Suarez-Farinas Mayte, Liharska Lora E, Thompson Ryan C, Del Valle Diane Marie, Beckmann Noam D, Lund Anina N, Gownivaripally Pooja, Oh Wonsuk, Gulamali Faris F, Kauffman Justin, Gonzalez-Kozlova Edgar, Dellepiane Sergio, Vasquez-Rios George, Vaid Akhil, Jiang Joy, Fox Ben, Sakhuja Ankit, Chen Steven, Kenigsberg Ephraim, He John Cijiang, Coca Steven G, Chan Lili, Merad Miram, Kim-Schulze Seunghee, Gnjatic Sacha, Tsalik Ephraim L, Langley Raymond, Charney Alexander W, Nadkarni Girish N
The Charles Bronfman Institute for Personalized Medicine (CBIPM), Icahn School of Medicine at Mount Sinai, New York, New York.
The Barbara T Murphy Division of Nephrology, Samuel Bronfman Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Kidney360. 2025 Feb 3;6(6):921-936. doi: 10.34067/KID.0000000727.
AKI in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is linked to mitochondrial dysfunction and cellular stress, highlighting novel biomarkers for severe AKI. Molecular similarities between AKI in SARS-CoV-2 and sepsis suggest that current therapeutic strategies may be applicable across both conditions. Molecular changes in acute SARS-CoV-2 infection are tied to long-term inflammation, immune dysregulation, and lasting cardiac and renal dysfunction.
AKI is common in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019, often leading to long-term kidney dysfunction. However, the transcriptomic features of AKI severity and its long-term effects are underexplored.
We performed bulk RNA sequencing on peripheral blood mononuclear cells from hospitalized patients with SARS-CoV-2 infection and complemented these findings with proteomic data from the same cohort. We compared the functional enrichment findings with historical sepsis–AKI data and subsequently examined the association between molecular signatures and long-term kidney function changes.
In 283 patients, 57 had mild AKI (stage 1) and 49 had severe AKI (stage 2 or 3). After adjustments for age, sex, severity of infection, and preexisting CKD, we identified 6432 differentially expressed genes in the severe AKI versus control comparison, 840 in the mild AKI versus control comparison, and 1213 in the severe versus mild AKI comparison (false discovery rate <0.05). Common pathways included unfolded protein response, cellular response to stress using eIF2, and IFN-–mediated inflammatory response. Severe AKI was linked to pathways involved in mitochondrial dysfunction and endoplasmic reticulum stress. Proteomic analysis confirmed 40 established AKI and inflammation biomarkers, whereas gene-set enrichment of transcription regulators revealed additional biomarkers for severe AKI. Comparison with peripheral blood mononuclear cell transcriptomics from sepsis-related AKI showed significant functional overlap (30%). Analysis of postdischarge eGFR data in 115 patients identified 177 differentially expressed genes for severe AKI versus control, 106 for mild AKI versus control, and 46 for severe versus mild AKI. Key associations included kidney function decline related to carbohydrate and mitochondrial metabolism, inflammatory-response, and cardiovascular regulation.
We demonstrate that severe AKI in SARS-CoV-2 infection is linked to mitochondrial dysfunction and endoplasmic reticulum stress. The functional overlap with sepsis–AKI suggests potential broader therapeutic applicability. Long-term kidney dysfunction is influenced by disruptions in cellular energy metabolism and immune response.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染中的急性肾损伤(AKI)与线粒体功能障碍和细胞应激有关,这凸显了严重AKI的新型生物标志物。SARS-CoV-2感染所致AKI与脓毒症之间的分子相似性表明,当前的治疗策略可能适用于这两种情况。急性SARS-CoV-2感染中的分子变化与长期炎症、免疫失调以及持久的心脏和肾脏功能障碍相关。
AKI在严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染和2019冠状病毒病中很常见,常导致长期肾功能障碍。然而,AKI严重程度的转录组学特征及其长期影响尚未得到充分研究。
我们对住院的SARS-CoV-2感染患者的外周血单核细胞进行了批量RNA测序,并用同一队列的蛋白质组学数据补充了这些发现。我们将功能富集结果与历史脓毒症相关AKI数据进行了比较,随后研究了分子特征与长期肾功能变化之间的关联。
在283例患者中,57例有轻度AKI(1期),49例有重度AKI(2期或3期)。在对年龄、性别、感染严重程度和既往慢性肾脏病进行调整后,我们在重度AKI与对照组的比较中鉴定出6432个差异表达基因,在轻度AKI与对照组的比较中鉴定出840个,在重度与轻度AKI的比较中鉴定出1213个(错误发现率<0.05)。常见途径包括未折叠蛋白反应、使用eIF2的细胞应激反应以及干扰素介导的炎症反应。重度AKI与线粒体功能障碍和内质网应激相关的途径有关。蛋白质组学分析证实了40种已确定的AKI和炎症生物标志物,而转录调节因子的基因集富集揭示了重度AKI的其他生物标志物。与脓毒症相关AKI的外周血单核细胞转录组学比较显示出显著的功能重叠(30%)。对115例患者出院后估算肾小球滤过率(eGFR)数据的分析确定了重度AKI与对照组之间有177个差异表达基因,轻度AKI与对照组之间有106个,重度与轻度AKI之间有46个。关键关联包括与碳水化合物和线粒体代谢、炎症反应及心血管调节相关的肾功能下降。
我们证明,SARS-CoV-2感染中的重度AKI与线粒体功能障碍和内质网应激有关。与脓毒症相关AKI的功能重叠表明可能有更广泛的治疗适用性。长期肾功能障碍受细胞能量代谢和免疫反应紊乱的影响。